PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men

Animal and human data indicate a role for the peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PPARGC1A) gene product in the development of maximal oxygen uptake ((V) over dot O-2 max), a determinant of endurance capacity, diabetes, and early death. We tested the hypothesis that the frequency of the minor Ser482 allele at the PPARGC1A locus is lower in World-class Spanish male endurance athletes ( cases) [ n = 104; mean (SD) age: 26.8 (3.8) yr] than in unfit United Kingdom (UK) Caucasian male controls [ n = 100; mean ( SD) age: 49.3 (8.1) yr]. In cases and controls, the Gly482Ser genotype met Hardy-Weinberg expectations ( P > 0.05 in both groups tested separately). Cases had significantly higher (V) over dot O-2 max [73.4 ( 5.7) vs. 29.4 ml center dot kg(-1) center dot min(-1) ( 3.8); P < 0.0001] and were leaner [ body mass index: 20.6 ( 1.5) vs. 27.6 kg/m(2) ( 3.9); P < 0.0001] than controls. In unadjusted chi(2) analyses, the frequency of the minor Ser482 allele was significantly lower in cases than in controls (29.1 vs. 40.0%; P = 0.01). To assess the possibility that genetic stratification could confound these observations, we also compared Gly482Ser genotype frequencies in Spanish ( n = 164) and UK Caucasian men ( n = 381) who were unselected for their level of fitness. In these analyses, Ser482 allele frequencies were very similar (36.9% in Spanish vs. 37.5% in UK Caucasians, P = 0.83), suggesting that confounding by genetic stratification is unlikely to explain the association between Gly482Ser genotype and endurance capacity. In summary, our data indicate a role for the Gly482Ser genotype in determining aerobic fitness. This finding has relevance from the perspective of physical performance, but it may also be informative for the targeted prevention of diseases associated with low fitness such as Type 2 diabetes.